Investor Center

Investors & Media

Stockholder Tools

Press Releases

Press Releases

June 15, 2020
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies
– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam
Read More
March 16, 2020
Beam Therapeutics Announces Key R&D Appointments
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key leadership appointments, including the promotion of Manmohan Singh, Ph.D., from vice president to
Read More
February 11, 2020
Beam Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2020-- Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in
Read More
February 5, 2020
Beam Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price
Read More
Displaying 1 - 10 of 11

Investors & Media

Stockholder Tools